ONE NUCLEUS STRENGTHENS BOARD WITH APPOINTMENT OF NEW DIRECTOR

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
SoluLyse™ from Amsbio is a bacterial protein extraction reagent that provides a highly efficient yet gentle method for extracting soluble proteins from bacterial cells.
Based upon a proprietary non-ionic detergent formulation, with the SoluLyse™ reagent there is no need for time-consuming and cumbersome secondary treatment methods such as sonication or freeze thaw. The unique, mild SoluLyse™ formulation allows perforation of bacterial cell walls without denaturing proteins.
Based at Alderley Park, Medicines Discovery Catapult is a national Life Sciences service dedicated to turning drug discovery into commercial breakthroughs. We accelerate the development of science, and where there are areas of unmet patient need, we stimulate innovation.
About the company: TTP is an employee-owned technology and product development consultancy, with a 40-year track record of helping ambitious clients solve complex challenges and bring innovative, commercially successful solutions to market.
We invent, design, and manufacture impactful products and technologies across a wide range of industries – including healthcare, life science, energy, and communications – and at the intersection of engineering, physical science, and biology.
![]()
|
Never losing sight of our purpose
At Mestag we truly believe in our values and live by them every day. We’re ambitious about our science and its potential to deliver meaningful therapeutics to the patients that need them most. We believe in a culture of diversity, equality and investing in people to ensure our talented and passionate team members can fulfil their full potential.
Ellipses Pharma is a global drug development company headquartered in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection, the expertise of a Scientific Affairs Group, which comprises more than 300 leading oncologists and an uninterrupted funding flow to minimise the time it takes to advance lead products through clinical trials and reach patients.
Join us for two exciting days that will showcase an exceptional line-up of academic and industry speakers exploring breakthrough stem cell technologies transforming drug discovery and therapeutic development.
Co-hosted by the Babraham Institute and Newcastle University, the Frontiers in Stem Cell Innovation Conference will feature key talks and panel discussion sessions focused on stem cell technologies, disease modelling, and translational research.
This December, we invite our customers and prospective partners to join Catalent for an exclusive open house in Swindon during England’s most enchanting season. As the streets sparkle with festive lights and holiday spirit, you’ll step into a rare opportunity to see how Zydis® ODT, the world’s leading orally disintegrating tablet technology, continues to transform patient-centric drug delivery.
IP education session by Stratagem: IP for Start- ups and SMEs: Leveraging your IP strategy to drive business growth and unlock funding opportunities.
18th November – Glasshouse 4-6pm
For all spin-outs, startups and SMEs. Join Stratagem for an exclusive event at the Cambridge Glasshouse to learn more about how having a well thought out IP strategy which aligns with your business plan and goals will help drive growth and unlock funding opportunities. We will share thoughts about what Investors expect to see in early due diligence.